第二代糖肽类抗生素的研究进展  

Advance of research on the second generation of glycopeptide antibiotics

作　　者：尚新艳[1] 阮丽军[2] 许激扬[1] 陈代杰[2] 

机构地区：[1]中国药科大学生命科学与技术学院,南京210009 [2]上海医药工业研究院

出　　处：《中国抗生素杂志》2007年第5期263-267,312,共6页Chinese Journal of Antibiotics

摘　　要：随着细菌耐药的不断升级,耐万古霉素肠球菌、高度耐糖肽类抗生素的金葡菌的出现,给临床抗感染治疗带来极大困难。开发新型糖肽类抗生素刻不容缓。人们对万古霉素等天然糖肽类抗生素进行化学修饰,得到了一系列有价值的衍生物,其中oritavancin、dalbavancin和telavancin已进入Ⅲ期临床和新药注册。本文对第二代糖肽类抗生素的结构特征、药效学与药动学特征以及临床应用作一综述。Development of resistance to antibacterial agents, especially the advent of vancomycin-resisrant Enterococcus （VRE） and glycopeptide-resistant Staphylococcus aureus （GRSA） is a mounting problem that continues to compromise the clinical effectiveness of anti-infectious drugs. It is essential to develop new glycopeptide antibiotics. Three of these new derivatives obtained by semi-synthesis starting from natural compounds, are now in clinical development （oritavancin and telavancin, as derivatives of vancomycin; and dalbavancin, as a derivative of teicoplanin）. The review focuses on the structures, pharmacokinetic and pharmacodynamic parameters and the clinical research status related to the second-generation glycopeptide antibiotics.

关 键 词：第二代糖肽类抗生素 ORITAVANCIN DALBAVANCIN TELAVANCIN 

分 类 号：R978.1[医药卫生—药品]